ARS Pharma submits response letter to FDA after further nasal epinephrine study
ARS Pharma has submitted a response letter to the FDA as it seeks approval for its neffy epinephrine nasal spray, which is designed to treat type I allergic reactions such as anaphylaxis, according to a company press release. “Based on multiple meetings with the FDA, we believe that we have responded fully and completely to the agency’s concerns and appreciate its insights along the